- Home
- Services
- united kingdom
- therapeutics develops
Show results for
Refine by
Therapeutics Develops Services In United Kingdom
5 services found
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
An important feature of antibody drugs is that they can be tailored making by genetic engineering and be prepared according to specific therapeutic needs. With the development of antibody genetic engineering technology, development of genetic engineered antibody as drug candidates is growing rapidly such as antibody-drug conjugates (ADC), ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Antibody characterization is important in research and biopharmaceutical development. All therapeutic proteins produced from current technologies have heterogeneities in the final product because various modifications occur during different stages of production. Due to these heterogeneities, thorough characterization is necessary for the reproducible and safe ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Creative Biolabs has extensive experience to offer the novel human or humanized antibody services for either therapeutic or laboratory applications. We have three routes in developing human antibodies. The first and most straightforward method is to screen our human antibody libraries. The second method is to immunize premade “humanized” mice and then ...
Manufactured by:Absolute Antibody Ltd based inRedcar, UNITED KINGDOM
Polyclonal antibodies are widely used reagents across research and diagnostics. They are generated by immunizing animals with an immunogen and harvesting the animals’ blood to obtain immunoreactive serum. While polyclonal antibodies offer a range of advantages such as excellent performance across different methods, they suffer from high batch-to-batch variability and require the continued ...
Manufactured by:Invicro, LLC based inNeedham, MASSACHUSETTS (USA)
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal and healthy tissue. Streamlined development, evaluation and clinical translation of radiopharmaceuticals requires a partner that has ...